713 related articles for article (PubMed ID: 28001445)
1. Long-Term Efficacy and Safety of Sensor Augmented Insulin Pump Therapy with Low-Glucose Suspend Feature in Patients with Type 1 Diabetes.
Gómez AM; Marín Carrillo LF; Muñoz Velandia OM; Rondón Sepúlveda MA; Arévalo Correa CM; Mora Garzón E; Cuervo Diaz MC; Henao Carrillo DC
Diabetes Technol Ther; 2017 Feb; 19(2):109-114. PubMed ID: 28001445
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of sensor augmented insulin pump therapy with low-glucose suspend feature in older adults: A retrospective study in Bogota, Colombia.
Morros-González E; Gómez AM; Henao Carrillo DC; Ursida V; Serrano S; Rondón Sepúlveda MA; Muñoz Velandia OM
Diabetes Metab Syndr; 2021; 15(3):649-653. PubMed ID: 33813236
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of sensor-augmented pump therapy (SAPT) with predictive low-glucose management in patients diagnosed with type 1 diabetes mellitus previously treated with SAPT and low glucose suspend.
Gómez AM; Henao DC; Imitola A; Muñoz OM; Sepúlveda MAR; Kattah L; Guerrero JS; Morros E; Llano JP; Jaramillo MG; León-Vargas F
Endocrinol Diabetes Nutr (Engl Ed); 2018 Oct; 65(8):451-457. PubMed ID: 29914817
[TBL] [Abstract][Full Text] [Related]
4. Maternal-Fetal Outcomes in 34 Pregnant Women with Type 1 Diabetes in Sensor-Augmented Insulin Pump Therapy.
Gómez AM; Marín Carrillo LF; Arévalo Correa CM; Muñoz Velandia OM; Rondón Sepúlveda MA; Silva Herrera JL; Henao Carrillo DC
Diabetes Technol Ther; 2017 Jul; 19(7):417-422. PubMed ID: 28731823
[TBL] [Abstract][Full Text] [Related]
5. "Let the Algorithm Do the Work": Reduction of Hypoglycemia Using Sensor-Augmented Pump Therapy with Predictive Insulin Suspension (SmartGuard) in Pediatric Type 1 Diabetes Patients.
Biester T; Kordonouri O; Holder M; Remus K; Kieninger-Baum D; Wadien T; Danne T
Diabetes Technol Ther; 2017 Mar; 19(3):173-182. PubMed ID: 28099035
[TBL] [Abstract][Full Text] [Related]
6. Long-term health economic benefits of sensor-augmented pump therapy vs continuous subcutaneous insulin infusion alone in type 1 diabetes: a U.K. perspective.
Roze S; Smith-Palmer J; Valentine WJ; Cook M; Jethwa M; de Portu S; Pickup JC
J Med Econ; 2016; 19(3):236-42. PubMed ID: 26510389
[TBL] [Abstract][Full Text] [Related]
7. Threshold-based insulin-pump interruption for reduction of hypoglycemia.
Bergenstal RM; Klonoff DC; Garg SK; Bode BW; Meredith M; Slover RH; Ahmann AJ; Welsh JB; Lee SW; Kaufman FR;
N Engl J Med; 2013 Jul; 369(3):224-32. PubMed ID: 23789889
[TBL] [Abstract][Full Text] [Related]
8. Numerical and clinical precision of continuous glucose monitoring in Colombian patients treated with insulin infusion pump with automated suspension in hypoglycemia.
Gómez AM; Marín Sánchez A; Muñoz OM; Colón Peña CA
Endocrinol Nutr; 2015 Dec; 62(10):485-92. PubMed ID: 26531841
[TBL] [Abstract][Full Text] [Related]
9. A cost-effectiveness analysis of sensor-augmented insulin pump therapy and automated insulin suspension versus standard pump therapy for hypoglycemic unaware patients with type 1 diabetes.
Ly TT; Brnabic AJ; Eggleston A; Kolivos A; McBride ME; Schrover R; Jones TW
Value Health; 2014 Jul; 17(5):561-9. PubMed ID: 25128049
[TBL] [Abstract][Full Text] [Related]
10. Effect of sensor-augmented insulin pump therapy and automated insulin suspension vs standard insulin pump therapy on hypoglycemia in patients with type 1 diabetes: a randomized clinical trial.
Ly TT; Nicholas JA; Retterath A; Lim EM; Davis EA; Jones TW
JAMA; 2013 Sep; 310(12):1240-7. PubMed ID: 24065010
[TBL] [Abstract][Full Text] [Related]
11. Predictors of Hypoglycemia in the ASPIRE In-Home Study and Effects of Automatic Suspension of Insulin Delivery.
Weiss R; Garg SK; Bergenstal RM; Klonoff DC; Bode BW; Bailey TS; Thrasher J; Schwartz F; Welsh JB; Kaufman FR;
J Diabetes Sci Technol; 2015 May; 9(5):1016-20. PubMed ID: 25986629
[TBL] [Abstract][Full Text] [Related]
12. Impact of Sensor-Augmented Pump Therapy with Predictive Low-Glucose Suspend Function on Glycemic Control and Patient Satisfaction in Adults and Children with Type 1 Diabetes.
Beato-Víbora PI; Quirós-López C; Lázaro-Martín L; Martín-Frías M; Barrio-Castellanos R; Gil-Poch E; Arroyo-Díez FJ; Giménez-Álvarez M
Diabetes Technol Ther; 2018 Nov; 20(11):738-743. PubMed ID: 30256132
[TBL] [Abstract][Full Text] [Related]
13. Prevention of hypoglycemia by using low glucose suspend function in sensor-augmented pump therapy.
Danne T; Kordonouri O; Holder M; Haberland H; Golembowski S; Remus K; Bläsig S; Wadien T; Zierow S; Hartmann R; Thomas A
Diabetes Technol Ther; 2011 Nov; 13(11):1129-34. PubMed ID: 21827318
[TBL] [Abstract][Full Text] [Related]
14. Effect of predicted low suspend pump treatment on improving glycaemic control and quality of sleep in children with type 1 diabetes and their caregivers: the QUEST randomized crossover study.
Schierloh U; Aguayo GA; Fichelle M; De Melo Dias C; Celebic A; Vaillant M; Barnard K; Cohen O; de Beaufort C
Trials; 2018 Dec; 19(1):665. PubMed ID: 30509293
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of sensor-augmented pump therapy versus standard insulin pump therapy in patients with type 1 diabetes in Denmark.
Roze S; de Portu S; Smith-Palmer J; Delbaere A; Valentine W; Ridderstråle M
Diabetes Res Clin Pract; 2017 Jun; 128():6-14. PubMed ID: 28432898
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Different Treatment Modalities for Type 1 Diabetes, Including Sensor-Augmented Insulin Regimens, in 52 Weeks of Follow-Up: A COMISAIR Study.
Šoupal J; Petruželková L; Flekač M; Pelcl T; Matoulek M; Daňková M; Škrha J; Svačina Š; Prázný M
Diabetes Technol Ther; 2016 Sep; 18(9):532-8. PubMed ID: 27482825
[TBL] [Abstract][Full Text] [Related]
17. Reduction in duration of hypoglycemia by automatic suspension of insulin delivery: the in-clinic ASPIRE study.
Garg S; Brazg RL; Bailey TS; Buckingham BA; Slover RH; Klonoff DC; Shin J; Welsh JB; Kaufman FR
Diabetes Technol Ther; 2012 Mar; 14(3):205-9. PubMed ID: 22316089
[TBL] [Abstract][Full Text] [Related]
18. Predictive Low-Glucose Suspend Reduces Hypoglycemia in Adults, Adolescents, and Children With Type 1 Diabetes in an At-Home Randomized Crossover Study: Results of the PROLOG Trial.
Forlenza GP; Li Z; Buckingham BA; Pinsker JE; Cengiz E; Wadwa RP; Ekhlaspour L; Church MM; Weinzimer SA; Jost E; Marcal T; Andre C; Carria L; Swanson V; Lum JW; Kollman C; Woodall W; Beck RW
Diabetes Care; 2018 Oct; 41(10):2155-2161. PubMed ID: 30089663
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of sensor-augmented pump therapy in two different patient populations with type 1 diabetes in Italy.
Nicolucci A; Rossi MC; D'Ostilio D; Delbaere A; de Portu S; Roze S
Nutr Metab Cardiovasc Dis; 2018 Jul; 28(7):707-715. PubMed ID: 29753586
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the Adherence to Continuous Glucose Monitoring in the Management of Type 1 Diabetes Patients on Sensor-Augmented Pump Therapy: The SENLOCOR Study.
Picard S; Hanaire H; Baillot-Rudoni S; Gilbert-Bonnemaison E; Not D; Reznik Y; Guerci B
Diabetes Technol Ther; 2016 Mar; 18(3):127-35. PubMed ID: 26950530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
